Skip to main content

Advertisement

Table 1 Comparison of the percentage inhibition of renal glucose reabsorption of different SGLT-inhibitors

From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Drug dosage Filtered glucose (g/24 h) (eGFRx mean glucose mg/mL) UGE (g/24 h) Absorbed glucose (g/24 h) Inhibition of glucose reabsorption (%) References
Sotagliflozin 150 mg 256 36 220 14.1 Zambrowicz et al. [15]
Sotagliflozin 300 mg 287.5 47 240 16.5
Sotagliflozin 200 mg, 200 mg bid, 400 mg ~60 Rosentock et al. [36]
Empagliflozin 2.5 mg 39 Heise et al. [37]
Empagliflozin 10 mg 46
Empagliflozin 25 mg 58
Empagliflozin 100 mg 64
Dapagliflozin 2.5 mg 191.16 52 139.16 27.2 List et al. [38]
Dapagliflozin 5 mg 207.6 64 143.6 55.7  
Dapagliflozin 10 mg 206.1 68 138.1 54.5
Dapagliflozin 20 mg 196.9 85 111.9 51.7
Dapagliflozin 50 mg 191.3 82 109.3 53.1
  1. Inhibition of glucose reabsorption values, when not available, were calculated from the difference between filtered glucose (calculated as the product of estimated GFR [39] and estimated average glucose [40], HbA1c derived) and excreted glucose (g/24 h UGE)